… –glucose cotransporter-2 inhibitor, dapagliflozin, reduced death and hospitalizations, and
… and reduced ejection fraction. In this analysis, we examine the effects of dapagliflozin on a …

… higher mean differences with dapagliflozin vs placebo (ie, 5.8 … Our findings confirm these
beneficial effects of dapagliflozin … to assess the effects of dapagliflozin on clinical outcomes …

… ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily)
or placebo, in addition to recommended therapy. The primary outcome was a composite of …

… Failure), the SGLT2 inhibitor dapagliflozin reduced the incidence of the … effect of dapagliflozin
varied according to baseline renal function. We also examined the effect of dapagliflozin …

… and reduced ejection fraction, use of dapagliflozin over 12 weeks did not affect mean NT-…
Benefits of dapagliflozin on clinically meaningful HF measures appear to extend to patients …

… We randomly assigned 6263 patients with heart failure and a left ventricular ejection
fraction of more than 40% to receive dapagliflozin (at a dose of 10 mg once daily) or matching …

… , including patients with and without T2D and those with ejection fraction above and below
60%. Patients treated with dapagliflozin also had a significant, clinically meaningful 20-m …

… -HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin,
… the augmentation of oral therapy, and the effects of dapagliflozin on these additional events. …

… ejection fraction (HFpEF), but the hemodynamic mechanisms underlying these benefits
remain unclear. This study sought to determine whether treatment with dapagliflozin affects …

… will determine the efficacy and safety of the SGLT2 inhibitor dapagliflozin, added to conventional
therapy, in a broad spectrum of patients with heart failure and reduced ejection fraction. …